Ofsa3.Sa
OFSA3.SA is a pharmaceutical company that generates revenue primarily through the development, production, and sale of pharmaceutical products.
Business. OFSA3.SA is a pharmaceutical company that generates revenue primarily through the development, production, and sale of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
OFSA3.SA is a pharmaceutical company that generates revenue primarily through the development, production, and sale of pharmaceutical products.
OFSA3.SA maintains a capital structure with a debt-to-equity ratio of 0.61, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 3.55, suggesting strong short-term liquidity. However, the risk assessment notes a key flag: net cash is negative after subtracting total debt, which may signal potential liquidity constraints.
In terms of profitability, OFSA3.SA reports a return on equity (ROE) of 27.9% and a return on assets (ROA) of 14.2%, both of which are strong indicators of efficient use of equity and assets. These figures suggest the company is performing well relative to its capital base, though direct comparisons to industry medians are not available in the provided data.
The company's revenue is not segmented by geographic region or product line in the available data, so it is not possible to assess geographic or segment concentration. This lack of segmentation limits the ability to evaluate exposure to specific markets or product lines.
Looking at growth, the outlook data is not provided in the input, so no numeric deltas or revenue growth projections can be assessed. However, the company's free cash flow of 17.8 million BRL indicates a capacity to reinvest or return capital to shareholders.
The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's dilution potential is low, and no adjustments have been applied to the valuation metrics, suggesting a stable capital structure.
Recent events, such as filings or transcripts, are not included in the input data, so no specific recent developments can be cited.
- OFSA3.SA has a strong liquidity position with a current ratio of 3.55.
- The company's ROE of 27.9% and ROA of 14.2% indicate strong profitability.
- The debt-to-equity ratio of 0.61 suggests a balanced capital structure.
- The company's free cash flow of 17.8 million BRL supports reinvestment or shareholder returns.
- The risk assessment indicates a medium liquidity risk and a low dilution risk.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- OFSA3.SA Market data — financials · 2026-05-28